- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Redwood City Today
By the People, for the People
Allspring Global Investments Reduces Guardant Health Holdings
Institutional investor trims stake in cancer diagnostics company
Apr. 2, 2026 at 7:07am
Got story updates? Submit your updates here. ›
Allspring Global Investments Holdings LLC, a major institutional investor, lowered its holdings in Guardant Health, Inc. (NASDAQ:GH) by 1.9% during the fourth quarter, according to a recent SEC filing. The firm owned 618,599 shares of the company's stock, valued at $62.9 million, after selling 12,256 shares.
Why it matters
Guardant Health is a leading provider of liquid biopsy cancer diagnostics, a rapidly growing field. Institutional investor activity in the company's stock can signal broader market sentiment and trends in the oncology diagnostics industry.
The details
Allspring Global Investments, an investment management firm, reduced its position in Guardant Health during the fourth quarter of 2025. The firm previously owned 630,855 shares but sold 12,256 shares, bringing its total holdings down to 618,599 shares worth $62.9 million. Allspring Global Investments now owns approximately 0.49% of Guardant Health's outstanding shares.
- Allspring Global Investments filed its 13F report with the SEC on April 2, 2026, disclosing the reduced Guardant Health holdings as of the end of Q4 2025.
- The shares were sold during the fourth quarter of 2025.
The players
Allspring Global Investments Holdings LLC
A major institutional investment management firm that owns a significant stake in Guardant Health.
Guardant Health, Inc.
A precision oncology company that specializes in blood-based cancer diagnostics, including its flagship Guardant360 liquid biopsy test.
The takeaway
This filing indicates that even as Guardant Health continues to grow and innovate in the liquid biopsy space, some institutional investors may be taking a more cautious approach and trimming their positions. However, the company still maintains strong institutional ownership, suggesting ongoing confidence in its long-term prospects.
